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Abstract 
The international, phase III, multi-centre AZA-001 trial demonstrated azacitidine (AZA) is the first treatment to significantly extend overall 
survival (OS) in higher risk myelodysplastic syndromes (MDS) patients (Fenaux (2007) Blood 110 817). The current treatment paradigm, 
which is based on a relationship between complete remission (CR) and survival, is increasingly being questioned (Cheson (2006) Blood 
108 419). Results of AZA-001 show CR is sufficient but not necessary to prolong OS (List (2008) Clin Oncol 26 7006). Indeed, the AZA 
CR rate in AZA-001 was modest (17%), while partial remission (PR, 12%) and haematological improvement (HI, 49%) were also 
predictive of prolonged survival. This analysis was conducted to assess the median number of AZA treatment cycles associated with 
achievement of first response, as measured by IWG 2000-defined CR, PR or HI (major + minor). The number of treatment cycles from 
first response to best response was also measured.
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Methods 
Patients (pts) with higher risk MDS (FAB: RAEB, RAEB-T, or 
CMML and IPSS: Int-2 or High) were included. Pts were 
randomized to AZA (75 mg/m
2/d SC x 7d q 28d) or to a 
conventional care regimen (CCR). AZA treatment was 
continued up to disease progression (or unacceptable toxicity), 
regardless of haematological response. Erythropoiesis 
stimulating agents were not allowed. 
 
Results 
In all, 358 pts were randomized (179 to AZA and 179 to CCR). 
Of the 179 AZA pts, 91 (51%) achieved a CR, PR or HI. For the 
91 pts who achieved an IWG response, the median number of 
cycles to first response was three (range: 1–22), 81% of pts 
achieved a first response by six cycles, and 90% achieved a 
first response by nine cycles. For 57% of responders (n=52), 
their first response was their best response; the remaining 43% 
(n=39) had an improvement in their response status at a median 
of approximately four additional treatment cycles (range 1–11 
treatment cycles) after their first response. 
 
Conclusions 
While many pts achieving a haematological response with AZA 
do so in early treatment cycles, continued AZA dosing can 
further improve pt responses. In the AZA-001 study, a 
significant OS benefit was observed compared with CCR. In this
study, AZA pts received a median of nine treatment cycles 
(range 1–39). For those achieving a response of HI or better, 
90% did so by nine cycles; more than 40% of responders later 
achieved an improved response. In the absence of 
unacceptable toxicity or disease progression, continued AZA 
treatment is appropriate and may maximize patient benefit. 
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